A New High-Potency Antidiabetic Sulfonylurea [N-(1-hexahydro-1-azepinyl)-N'-p-tolyl-sulfonylurea].

U-17835 ([N-(1-hexahydro-1-azepinyl)-N′-p-tolyl-sulfonylurea]), a new blood sugar lowering sulfonylurea, was 4-6 times more active than tolbutamide in intact rats and 4 times more active in adrenalectomized rats. At equipotent doses it was not longer acting than tolbutamide in intact rats. Normal human subjects showed U-17835 to be 6-7 times more effective than tolbutamide in lowering blood sugar after a single dose. In 3 diabetic patients, U-17835, given for 8 weeks, was found to be 5-10 times more active than tolbutamide, and it showed no signs of intolerance. This compound was also better tolerated than tolbutamide in both rats and mice.